Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study

Lancet Neurology

Volumn 5, Issue 3, 2006, Pages 228-234

  Hansson, Oskar ^a,b   Zetterberg, Henrik ^c   Buchhave, Peder ^a,b   Londos, Elisabet ^a,b   Blennow, Kaj ^c   Minthon, Lennart ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; HOMOCYSTEINE; PHOSPHOPROTEIN; TAU PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EDUCATION; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX RATIO;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; ODDS RATIO; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TAU PROTEINS; TIME FACTORS;

EID: 32544435900     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70355-6     Document Type: Article

References (42)

1. CP Ferri, M Prince, C Brayne Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117
2. JL Price, JC Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368
3. C DeCarli Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment Lancet Neurol 2 2003 15 21
4. RC Petersen Mild cognitive impairment as a diagnostic entity J Intern Med 256 2004 183 194
5. K Blennow, H Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613
6. ST DeKosky, K Marek Looking backward to move forward: early detection of neurodegenerative disorders Science 302 2003 830 834
7. PT Lansbury Jr Back to the future: the 'old-fashioned' way to new medications for neurodegeneration Nat Med 10 suppl 2004 S51 S57
8. H Hampel, SJ Teipel, T Fuchsberger Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Mol Psychiatry 9 2004 705 710
9. M Maruyama, T Matsui, H Tanji Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways Arch Neurol 61 2004 716 720
10. JG Lijmer, BW Mol, S Heisterkamp Empirical evidence of design-related bias in studies of diagnostic tests JAMA 282 1999 1061 1066
11. L Irwig, AN Tosteson, C Gatsonis Guidelines for meta-analyses evaluating diagnostic tests Ann Intern Med 120 1994 667 676
12. MC Reid, MS Lachs, AR Feinstein Use of methodological standards in diagnostic test research: getting better but still not good JAMA 274 1995 645 651
13. S Oddo, L Billings, JP Kesslak, DH Cribbs, FM LaFerla Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 2004 321 332
14. K Santacruz, J Lewis, T Spires Tau suppression in a neurodegenerative mouse model improves memory function Science 309 2005 476 481
15. MF Folstein, SE Folstein, PR McHugh "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
16. RC Mohs, D Knopman, RC Petersen Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope Alzheimer Dis Assoc Disord 11 suppl 2 1997 S13 S21
17. PJ Manos, R Wu The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients Int J Psychiatry Med 24 1994 229 244
18. RC Petersen, GE Smith, SC Waring, RJ Ivnik, EG Tangalos, E Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308
19. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders third edn, revised 1987 American Psychiatric Association Arlington, VA, USA
20. SE Vermeer, ND Prins, T den Heijer, A Hofman, PJ Koudstaal, MM Breteler Silent brain infarcts and the risk of dementia and cognitive decline N Engl J Med 348 2003 1215 1222
21. PJ Visser, P Scheltens, FR Verhey Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 76 2005 1348 1354
22. G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
23. GC Roman, TK Tatemichi, T Erkinjuntti Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 43 1993 250 260
24. IG McKeith, EK Perry, RH Perry Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies Neurology 53 1999 902 905
25. A Brun, E Englund, L Gustafson Clinical and neuropathological criteria for frontotemporal dementia J Neurol Neurosurg Psychiatry 57 1994 416 418
26. A Olsson, H Vanderstichele, N Andreasen Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345
27. WJ Youden Index for rating diagnostic tests Cancer 3 1950 32 35
28. A Maddalena, A Papassotiropoulos, B Muller-Tillmanns Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42 Arch Neurol 60 2003 1202 1206
29. B Ibach, H Binder, M Dragon Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample Neurobiol Aging 2005 Published online August 4. DOI:10.1016/j.neurobiolaging.2005.06.005
30. SK Herukka, M Hallikainen, H Soininen, T Pirttila CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment Neurology 64 2005 1294 1297
31. AF Jorm, D Jolley The incidence of dementia: a meta-analysis Neurology 51 1998 728 733
32. PJ Nestor, P Scheltens, JR Hodges Advances in the early detection of Alzheimer's disease Nat Med 10 suppl 2004 S34 S41
33. CR Jack Jr, MM Shiung, SD Weigand Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI Neurology 65 2005 1227 1231
34. ES Korf, LO Wahlund, PJ Visser, P Scheltens Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment Neurology 63 2004 94 100
35. I Skoog, P Davidsson, O Aevarsson, H Vanderstichele, E Vanmechelen, K Blennow Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds Dem Geriatr Cogn Disord 15 2003 169 176
36. M Moonis, JM Swearer, MP Dayaw Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline Neurology 65 2005 323 325
37. T Sunderland, N Mirza, KT Putnam Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele Biol Psychiatry 56 2004 670 676
38. EM Reiman, RJ Caselli, LS Yun Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N Engl J Med 334 1996 752 758
39. SY Bookheimer, MH Strojwas, MS Cohen Patterns of brain activation in people at risk for Alzheimer's disease N Engl J Med 343 2000 450 456
40. LJ Thal, SH Ferris, L Kirby A randomised, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 2005 1204 1215
41. RC Petersen, RG Thomas, M Grundman Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2005 2379 2388
42. JM Orgogozo, S Gilman, JF Dartigues Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46 54